ACR SOTA Highlights 2025
$59900
SOTA2025EA
Basic & Clinical Sciences, Inflammatory Myopathies, Lupus, Other Rheumatic & Connective Tissue Disorders, Rheumatoid Arthritis, Vasculitides
Friday, May 2, 2025, 1:00 AM
Monday, May 1, 2028, 11:55 PM
CME, MOC
Advanced Practice Nurses, Division Directors, Epidemiologists, Fellows in Training, Nurses, Pharmacists, Primary Care Providers, Physician Assistants, Residents, Rheumatologists, Rheumatology Interprofessionals
7.50
7.50

Activity Information

The ACR’s State-of-the-Art Clinical Symposium (SOTA) includes lectures from key opinion leaders, plus a Q&A session for each. The lectures encompass a variety of topics, including new therapies and indications in rheumatic disease treatment, large vessel vasculitis, pregnancy and reproductive health, and lupus in diverse skin types.


The activity includes the following sessions:

  • Rheumatic Disease Treatment
  • Biosimilars in Rheumatology
  • Large Vessel Vasculitis Imaging
  • New Concepts in Relapsing Polychondritis
  • Deciphering IgG4-Related Disease
  • Demystifying Pain and Fatigue in Lupus
  • Lupus in Color: Cutaneous Lupus in Diverse Skin Types
  • Pregnancy and Reproductive Health in Rheumatology
  • Unraveling Hypermobility Disorders
  • Idiopathic Inflammatory Myopathy-Associated Cancer Screening Updates

 

Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.

ACR/ARP Member: $399
ACR/ARP Potential Member: $599


Target Audience

Rheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.


Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Recognize and differentiate the clinical presentations and phenotypes of patients with complex rheumatic diseases, including relapsing polychondritis, IgG4-related disease, and hypermobility syndromes, to enhance diagnostic accuracy and individualized patient care.
  • Discuss the most up-to-date evidence-based treatment approaches, including novel therapies, in the management of a variety of rheumatic diseases, including relapsing polychondritis, osteoporosis, and spondyloarthritis.
  • Discuss and implement current recommendations regarding pregnancy and reproductive health issues pertinent to women and men with rheumatic disease.
  • Summarize and apply guidelines for cancer screening in myositis, with a focus on identifying specific subtypes that necessitate more intensive monitoring, to enhance early detection and improve patient outcomes in this vulnerable population.



CE and MOC Information

CME

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

The American College of Rheumatology designates this Enduring Material for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME credit must be claimed by May 1, 2028, at 11:59 PM ET.


MOC

MOC Recognition Statement: American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. 

After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.

 

MOC points must be claimed by May 1, 2028, at 11:59 PM ET.


Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

  1. Advisor or review panel member
  2. Consultant
  3. Employee
  4. Officer or Board Member
  5. Grant/research support
  6. Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
  7. Independent contractor
  8. Executive role and/or ownership interest
  9. Royalties and/or patent beneficiary
  10. Intellectual property/patents
  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
  12. Private investigator
  13. Expert witness
  14. Equity interest
  15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. State-of-the-Art Clinical Symposium 2025 Financial Relationship Disclosures.


Acknowledgement of Commercial Support

No commercial support was provided for this activity.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.

ACR SOTA Highlights 2025

Watch lectures from a range of content in areas such as therapeutic developments, recent research findings, and scientific advances, including the questions and answer sessions, from ACR’s State-of-the-Art Clinical Symposium 2025.